Clinical factors predictive of recurrent febrile neutropenia in adult patients with acute leukemia.

Autor:	Wanitpongpun C; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand., Teawtrakul N; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand., Lanamtieng T; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand., Chansung K; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand., Sirijeerachai C; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand., Amampai W; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand., Sawanyawisuth K; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Jazyk:	angličtina
Zdroj:	Leukemia research reports [Leuk Res Rep] 2022 Feb 15; Vol. 17, pp. 100296. Date of Electronic Publication: 2022 Feb 15 (Print Publication: 2022).
DOI:	10.1016/j.lrr.2022.100296
Abstrakt:	Febrile neutropenia (FN) is considered an oncologic emergency in acute leukemia. There were 250 FN events in 124 hospitalized patients with hematologic malignancy. These data imply that two FN events may occur per patient, yet data on the prevalence, risk factors, and outcomes of recurrent FN in adult patients with leukemia are limited. A retrospective cohort study was conducted that enrolled adult patients diagnosed with acute leukemia who developed FN. The eligible patients were categorized as with or without recurrent FN. A stepwise, multivariate logistic regression analysis was performed to identify predictors of recurrent FN. A total of 203 patients met the study criteria; of these, 46 (22.66%) had recurrent FN, and this group had a median of three recurrent FN emergencies. After adjusted, three independent factors remained in the final model including ALL, FN at admission, and treatment with idarubicin (3 days) and cytarabine (7 days). The three factors were positively associated with recurrent FN with adjusted odds ratios of 6.253, 4.068, and 10.757, respectively. No significant differences were found between the two groups in terms of other sources of infection, other pathogens, ICU stay, hospital stay, and mortality. ALL and FN at admission and treatment with idarubicin (3 days) and cytarabine (7 days) were associated with recurrent FN in acute leukemia patients with FN. Clinical outcomes for patients with or without recurrent FN were mostly comparable; however, due to its small sample size, further studies are required to confirm the results of this study. Competing Interests: The authors declare that they have no competing interests. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu